• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » The History of Depakote

The History of Depakote

July 1, 2008
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Valproate originally saw the light of day in the German laboratory of Beverly Burton, in 1882. She was engaged in research on fatty acids, and synthesized a new one, called 2-propylvaleric acid. But she was not able to make this acid into a salt, which is necessary in order to turn it into a solid form, and so she stopped working on it. The compound resurfaced in the 1940s when German scientists were working on creating food substitutes as part of the war effort. They succeeded in turning coal into a mixture of triglycerides that tasted a bit like butter, and they called it ersatzbutter. In analyzing this promising substance, they isolated the same acid that Beverly Burton had discovered in 1882. They gave it a new name, valproic acid. It turned out that it was not very useful as a nutritional supplement, however, because most of it was excreted unchanged. However, it was useful as a solvent, and it found use as a way of dissolving other drugs for research in laboratories. Fast forward to 1960, in a pharmacology laboratory at the University of Grenoble. Pierre Eymard was trying to develop a plant derivative called khelline as an antispasmodic. But he kept facing a stumbling block – khelline was very hard to dissolve. He learned about the wonderful solvent effects of valproic acid, and used it to dissolve khelline. When he injected this mixture into patients, it produced profound relaxation, leading Eymard’s supervisor, Carraz, to screen valproic acid for behavioral effects. Carraz added sodium to it, creating sodium valproate, eventually doing studies of epileptics, leading to its first wide clinical use as an anticonvulsant.

In 1983, Abbott obtained a license for its use in the U.S., and came up with a new way of making the salt – by adding another sodium ion, turning it into sodium divalproate. They received a patent for this, because they successfully argued that it was easier on the stomach than valproic acid. Eventually, “Depakote” received FDA approval for the treatment of both epilepsy and bipolar disorder.

Source: David Healy, Mania: A Short History of Bipolar Disorder. Baltimore: The Johns Hopkins University Press, 2008.
General Psychiatry
KEYWORDS pharmacology
    www.thecarlatreport.com
    Issue Date: July 1, 2008
    SUBSCRIBE NOW
    Table Of Contents
    Antidepressants and Bipolar Disorder: An Update
    Lamictal: What is it Good For?
    Weight Gain and Mood Stabilizers
    The Case in Favor of the Bipolar Spectrum
    Is Bipolar Disorder Overdiagnosed?
    SSRIs show weak advantage over bupropion for anxious depression
    Computer as psychotherapist?
    The History of Depakote
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.